US20080269872A1 - Stent - Google Patents

Stent Download PDF

Info

Publication number
US20080269872A1
US20080269872A1 US12/108,571 US10857108A US2008269872A1 US 20080269872 A1 US20080269872 A1 US 20080269872A1 US 10857108 A US10857108 A US 10857108A US 2008269872 A1 US2008269872 A1 US 2008269872A1
Authority
US
United States
Prior art keywords
stent
trusses
predetermined breaking
webs
joint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/108,571
Other versions
US8876885B2 (en
Inventor
Daniel Lootz
Bettina Surber
Mathias Haussmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotronik AG
Original Assignee
Biotronik VI Patent AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotronik VI Patent AG filed Critical Biotronik VI Patent AG
Assigned to BIOTRONIK VI PATENT AG reassignment BIOTRONIK VI PATENT AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAUSSMANN, MATHIAS, SURBER, BETTINA, LOOTZ, DANIEL
Publication of US20080269872A1 publication Critical patent/US20080269872A1/en
Application granted granted Critical
Publication of US8876885B2 publication Critical patent/US8876885B2/en
Assigned to BIOTRONIK AG reassignment BIOTRONIK AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOTRONIK VI PATENT AG
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A61F2002/9155Adjacent bands being connected to each other
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A61F2002/9155Adjacent bands being connected to each other
    • A61F2002/91591Locking connectors, e.g. using male-female connections
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0004Rounded shapes, e.g. with rounded corners
    • A61F2230/0013Horseshoe-shaped, e.g. crescent-shaped, C-shaped, U-shaped
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0071Additional features; Implant or prostheses properties not otherwise provided for breakable or frangible

Definitions

  • the present disclosure relates to stents.
  • U.S. Patent Publication No. 2006/0122694 A1 discloses a stent which comprises an essentially tubular open supporting structure of interconnected webs. This supporting structure is radially distensible with deformation of the webs formed by interconnected trusses in sections for application of the stent in a blood vessel in a patient.
  • predetermined breaking points are also integrated into the supporting structure, serving to fragment the stent after application.
  • this fragmentation serves to break apart the electrically conductive conductor loop formed by the peripheral trusses to thereby increase the visibility of the body material in the lumen surrounded by the stent in a magnetic resonance examination. Since the integrity of the webs is still guaranteed during application of the stent, this stent has enough stability to ensure the desired vasodilation through its application.
  • the predetermined breaking points are formed by bridges of material within the stent webs made of a material having a greater corrodability.
  • the predetermined breaking points may be formed by a cross-sectional constriction which leads to a defined dissolution of the structural stability of the stent in the area of the predetermined breaking point due to the corrosion of the stent that occurs there.
  • Magnesium and its alloys are, however, at risk of breakage under corrosive stress and/or vibrating stress at the same time, such as that to which a stent administered in a pulsating bloodstream is exposed.
  • local spots of corrosion may occur, e.g., due to irregularities in the material or the surface.
  • Stents such as those known from European Patent Application No. 1 430 854 A1, for example, may thus be subject to the risk of uncontrolled fragmentation after initial deformation for radial widening of the stent so that the supportive function of such a stent is at risk, in particular, in the arterial blood vessels. The reason for this is that individual web elements in the area of uncontrolled fragmentation no longer have a structural mechanical cohesion and the supportive function of the stents is lost with an increasing number of fragments formed.
  • a stent comprising a) an essentially tubular open supporting structure of interconnected trusses, each truss having a first end and a second end, whereby the supporting structure can be widened radially with deformation of the trusses for application of the stent; b) predetermined breaking points in the supporting structure for fragmentation of the stent after application; and, c) the ends of the trusses that are adjacent to the respective predetermined breaking point which is provided in the area of the predetermined breaking point, having a joint design such that the ends of the trusses are held together with an articulation under an applied pressure with the predetermined breaking point broken.
  • the present disclosure provides a stent which prevents or reduces uncontrolled fragmentation, in particular, when using a material for a stent that is at risk of breakage.
  • the present disclosure is thus based on a diametrically opposite concept in comparison with the state of the art, namely, controlled fragmentation in the area of the predetermined breaking points of the supporting structure takes place in such a way that the point in time of the local breaking of the stent areas takes place in a defined manner and is controllable through the shape of the stent.
  • controlled fragmentation in the area of the predetermined breaking points of the supporting structure takes place in such a way that the point in time of the local breaking of the stent areas takes place in a defined manner and is controllable through the shape of the stent.
  • Another advantage of this controlled fragmentation is that the stent is better adaptable in its structure to materials having a reduced elongation at break and/or tensile strength or bending strength.
  • the controlled fragmentation leads to a reduction in stress in the areas that are under load radially, so that uncontrolled stress corrosion can no longer occur.
  • FIG. 1 is a longitudinal side view of a stent according to one exemplary embodiment
  • FIG. 2 is a schematic view of a detail in a developed representation of four rows of webs of the stent of FIG. 1 in a contracted state;
  • FIG. 3 is a schematic view of a neighboring truss end in the area of a predetermined breaking point during and after fragmentation;
  • FIG. 4 is a schematic view of a second neighboring truss end in the area of a predetermined breaking point during and after fragmentation;
  • FIG. 5 is a view of the four rows of stents as shown in FIG. 2 in an expanded state of the stent;
  • FIG. 6 is a schematic enlarged view of the ends of two neighboring trusses with a predetermined breaking point in a first alternative embodiment
  • FIG. 7 is a schematic radial section through a stent with a predetermined breaking point in a second alternative embodiment.
  • FIG. 1 shows a stent 1 having a basic cylindrical shape with a longitudinal axis 2 .
  • the circumferential wall of the stent is formed by an open tubular supporting structure 4 consisting of interconnected webs 6 .
  • These webs 6 have a helical primary shape in the circumferential direction U.
  • the webs 6 are designed to be meandering in the circumferential direction, whereby the meandering curves have zeniths 7 pointing toward the stent ends.
  • the webs 6 running side by side are interconnected by axial connectors 8 .
  • the entire latticework of the supporting structure 4 is shaped out of a cylindrical blank, e.g., made of a magnesium alloy, by laser cutting.
  • FIG. 2 shows the fine structure of the webs 6 that were omitted from FIG. 1 in greater detail for the sake of simplicity.
  • the meandering shape of the webs 6 is composed of zigzag-shaped trusses 9 going back and forth between the zeniths 7 in sections.
  • the ends 10 , 11 of the trusses 9 have different structures.
  • the one truss end 10 is designed with a shape 12 like a joint socket while the opposite end 11 is designed as a joint ball 13 .
  • the joint ball 13 is situated at the end of a bend 16 provided with an external rounded surface 15 .
  • the diameter of the joint ball 13 is definitely smaller than the inside diameter of the joint socket 12 .
  • the joint socket 12 and joint ball 13 are referred to as two-dimensional with respect to the actual joint site because the entire structure of the stent is cut out of the lateral surface of the aforementioned blank so that joint axis G is directed radially.
  • a one-piece breaking web 14 which functions as the predetermined breaking point for the supporting structure 4 within the joint design comprising the joint socket 12 and the joint ball 13 , is provided between the joint socket 12 and the joint ball 13 . Due to their small width, the narrow breaking webs 14 have a cross-sectional area that is many times smaller than that of the actual web.
  • the angles W between the trusses 9 are greatly increased by bending in the expansion of the stent 1 during application of the stent in a blood vessel.
  • the bending moment exerted on the trusses ensures breaking of the breaking webs 14 so the predetermined breaking points within the webs 6 are released.
  • the joint balls 13 come to lie cleanly in the corresponding joint sockets 12 and are thus held together like a joint. This means that the widening of the stent can be accomplished without having problematical stress peaks act on the stent structure.
  • the forces holding the joint socket 12 and the joint ball 13 together are created by the radial force acting on the stent due to the blood vessel are indicated by arrow 19 in FIG. 5 .
  • the predetermined breaking point is formed between the two ends 10 , 11 of two neighboring trusses 9 through a through-hole 17 created radially in the supporting structure so that two breaking webs 14 . 1 , 14 . 2 running side by side are provided.
  • a predetermined breaking point may be provided between two neighboring ends 10 , 11 of the trusses 9 through a blind hole or a blind slot 18 , as shown in FIG. 6 .

Abstract

A stent comprising an essentially tubular open supporting structure (4) of interconnected trusses (9), whereby the supporting structure (4) can be widened radially with deformation of the trusses (9) for application of the stent, and predetermined breaking points (14) in the supporting structure (4) for fragmentation of the stent after application, and the ends (10, 11) of the trusses (9) that are adjacent to the respective predetermined breaking point (14) having a joint design and which are provided in the area of the predetermined breaking point (14), such that the ends (10, 11) of the trusses (9) are held together with articulation under an applied pressure with the predetermined breaking point (14) broken.

Description

    PRIORITY CLAIM
  • This patent application claims priority to German Patent Application No. 10 2007 019 703.0, filed Apr. 26, 2007, the disclosure of which is incorporated herein by reference in its entirety.
  • FIELD
  • The present disclosure relates to stents.
  • BACKGROUND
  • Stents are well known in the art. U.S. Patent Publication No. 2006/0122694 A1, for example, discloses a stent which comprises an essentially tubular open supporting structure of interconnected webs. This supporting structure is radially distensible with deformation of the webs formed by interconnected trusses in sections for application of the stent in a blood vessel in a patient.
  • With the previously known stent, predetermined breaking points are also integrated into the supporting structure, serving to fragment the stent after application. As mentioned in the U.S. patent publication cited above, this fragmentation serves to break apart the electrically conductive conductor loop formed by the peripheral trusses to thereby increase the visibility of the body material in the lumen surrounded by the stent in a magnetic resonance examination. Since the integrity of the webs is still guaranteed during application of the stent, this stent has enough stability to ensure the desired vasodilation through its application.
  • With the known stent, the predetermined breaking points are formed by bridges of material within the stent webs made of a material having a greater corrodability. As an alternative to this, the predetermined breaking points may be formed by a cross-sectional constriction which leads to a defined dissolution of the structural stability of the stent in the area of the predetermined breaking point due to the corrosion of the stent that occurs there.
  • The more recent development in the field of stents provides for the use of magnesium and its alloys as the materials. These materials are biodegradable and thus lead to the desired dissolution of the stent after widening the blood vessel and its inherent stabilization. This prevents the problem whereby the stent, acting as a foreign body, tends to an accumulation of cells over a period of time, and therefore the treated blood vessel becomes occluded by a restenosis.
  • Magnesium and its alloys are, however, at risk of breakage under corrosive stress and/or vibrating stress at the same time, such as that to which a stent administered in a pulsating bloodstream is exposed. In addition, local spots of corrosion may occur, e.g., due to irregularities in the material or the surface. Stents such as those known from European Patent Application No. 1 430 854 A1, for example, may thus be subject to the risk of uncontrolled fragmentation after initial deformation for radial widening of the stent so that the supportive function of such a stent is at risk, in particular, in the arterial blood vessels. The reason for this is that individual web elements in the area of uncontrolled fragmentation no longer have a structural mechanical cohesion and the supportive function of the stents is lost with an increasing number of fragments formed.
  • SUMMARY
  • The present disclosure describes several exemplary embodiments of the present invention.
  • One aspect of the present disclosure provides a stent comprising a) an essentially tubular open supporting structure of interconnected trusses, each truss having a first end and a second end, whereby the supporting structure can be widened radially with deformation of the trusses for application of the stent; b) predetermined breaking points in the supporting structure for fragmentation of the stent after application; and, c) the ends of the trusses that are adjacent to the respective predetermined breaking point which is provided in the area of the predetermined breaking point, having a joint design such that the ends of the trusses are held together with an articulation under an applied pressure with the predetermined breaking point broken.
  • Based on the disadvantages associated with the state of the art as described here, the present disclosure provides a stent which prevents or reduces uncontrolled fragmentation, in particular, when using a material for a stent that is at risk of breakage.
  • This is achieved by the features of the present disclosure whereby an articular embodiment of the ends adjacent to the respective predetermined breaking point of the trusses forming the webs is provided such that the ends of the trusses are held together in an articulated manner when the predetermined breaking point is broken under a pressure acting on the stent.
  • The present disclosure is thus based on a diametrically opposite concept in comparison with the state of the art, namely, controlled fragmentation in the area of the predetermined breaking points of the supporting structure takes place in such a way that the point in time of the local breaking of the stent areas takes place in a defined manner and is controllable through the shape of the stent. Through the design of the joint in the area of the predetermined breaking points, in this context a weakening of the structure is avoided to the extent that the stent can still maintain its supporting effect for a sufficiently long period of time despite the fragmentation. The reason for this is the controlled joining of the adjacent ends of the truss at the predetermined breaking point due to the radial load originating from the blood vessel. The trusses thus act with a supporting effect under pressure radially despite the loss of integration.
  • Another advantage of this controlled fragmentation is that the stent is better adaptable in its structure to materials having a reduced elongation at break and/or tensile strength or bending strength. The controlled fragmentation leads to a reduction in stress in the areas that are under load radially, so that uncontrolled stress corrosion can no longer occur.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • Various aspects of the present disclosure are described hereinbelow with reference to the accompanying figures in which like reference characters represent the same or similar parts throughout the several views, of which:
  • FIG. 1 is a longitudinal side view of a stent according to one exemplary embodiment;
  • FIG. 2 is a schematic view of a detail in a developed representation of four rows of webs of the stent of FIG. 1 in a contracted state;
  • FIG. 3 is a schematic view of a neighboring truss end in the area of a predetermined breaking point during and after fragmentation;
  • FIG. 4 is a schematic view of a second neighboring truss end in the area of a predetermined breaking point during and after fragmentation;
  • FIG. 5 is a view of the four rows of stents as shown in FIG. 2 in an expanded state of the stent;
  • FIG. 6 is a schematic enlarged view of the ends of two neighboring trusses with a predetermined breaking point in a first alternative embodiment; and
  • FIG. 7 is a schematic radial section through a stent with a predetermined breaking point in a second alternative embodiment.
  • DETAILED DESCRIPTION
  • FIG. 1 shows a stent 1 having a basic cylindrical shape with a longitudinal axis 2. The circumferential wall of the stent is formed by an open tubular supporting structure 4 consisting of interconnected webs 6. These webs 6 have a helical primary shape in the circumferential direction U. As this superimposed secondary shape, the webs 6 are designed to be meandering in the circumferential direction, whereby the meandering curves have zeniths 7 pointing toward the stent ends. In isolated positions, the webs 6 running side by side are interconnected by axial connectors 8. The entire latticework of the supporting structure 4 is shaped out of a cylindrical blank, e.g., made of a magnesium alloy, by laser cutting.
  • FIG. 2 shows the fine structure of the webs 6 that were omitted from FIG. 1 in greater detail for the sake of simplicity. The meandering shape of the webs 6 is composed of zigzag-shaped trusses 9 going back and forth between the zeniths 7 in sections. The ends 10, 11 of the trusses 9 have different structures. The one truss end 10 is designed with a shape 12 like a joint socket while the opposite end 11 is designed as a joint ball 13. The joint ball 13 is situated at the end of a bend 16 provided with an external rounded surface 15. The diameter of the joint ball 13 is definitely smaller than the inside diameter of the joint socket 12. The joint socket 12 and joint ball 13 are referred to as two-dimensional with respect to the actual joint site because the entire structure of the stent is cut out of the lateral surface of the aforementioned blank so that joint axis G is directed radially.
  • As FIG. 3 shows clearly, a one-piece breaking web 14, which functions as the predetermined breaking point for the supporting structure 4 within the joint design comprising the joint socket 12 and the joint ball 13, is provided between the joint socket 12 and the joint ball 13. Due to their small width, the narrow breaking webs 14 have a cross-sectional area that is many times smaller than that of the actual web.
  • As shown clearly in FIGS. 2-5, the angles W between the trusses 9 are greatly increased by bending in the expansion of the stent 1 during application of the stent in a blood vessel. The bending moment exerted on the trusses ensures breaking of the breaking webs 14 so the predetermined breaking points within the webs 6 are released. Under the radial pressure exerted by the blood vessel on the stent 1, the joint balls 13 come to lie cleanly in the corresponding joint sockets 12 and are thus held together like a joint. This means that the widening of the stent can be accomplished without having problematical stress peaks act on the stent structure. The forces holding the joint socket 12 and the joint ball 13 together are created by the radial force acting on the stent due to the blood vessel are indicated by arrow 19 in FIG. 5.
  • In the exemplary embodiment shown in FIG. 6, the predetermined breaking point is formed between the two ends 10, 11 of two neighboring trusses 9 through a through-hole 17 created radially in the supporting structure so that two breaking webs 14.1, 14.2 running side by side are provided. As an exemplary alternative, a predetermined breaking point may be provided between two neighboring ends 10, 11 of the trusses 9 through a blind hole or a blind slot 18, as shown in FIG. 6.
  • In general, a reduction in cross section to 10% of the cross-sectional area of the trusses 9 can be implemented. This depends on the particular material used and can be determined by simple experiments.
  • All patents, patent applications and publications referred to herein are incorporated by reference in their entirety.

Claims (10)

1. A stent, comprising:
a) an essentially tubular open supporting structure of interconnected trusses, each truss having a first end and a second end, whereby the supporting structure can be widened radially with deformation of the trusses for application of the stent;
b) predetermined breaking points in the supporting structure for fragmentation of the stent after application; and
c) the ends of the trusses that are adjacent to the respective predetermined breaking point which is provided in the area of the predetermined breaking point, having a joint design such that the ends of the trusses are held together with an articulation under an applied pressure with the predetermined breaking point broken.
2. The stent of claim 1, wherein the ends of the trusses adjacent to a respective predetermined breaking point are designed as a joint socket with a joint socket shape on one truss end and a shape like a joint ball on the second truss end.
3. The stent of claim 2, wherein the joint socket has a joint axis running radially with respect to the stent.
4. The stent of claim 1, wherein the predetermined breaking points are designed as breaking webs connecting the ends of the respective trusses.
5. The stent of claim 4, wherein the breaking webs have a smaller width in comparison to the trusses.
6. The stent of claim 4, wherein the breaking webs have a smaller thickness in comparison to the trusses.
7. The stent of claim 4, wherein at least two breaking webs are provided in a predetermined breaking point.
8. The stent of claim 1, further comprising webs running in a meandering pattern in the peripheral direction, wherein the predetermined breaking points are arranged with the joint design in the area of the zeniths of the webs.
9. The stent of claim 2, wherein the joint ball shape is formed by an externally rounded bend of the truss end.
10. The stent of claim 4, wherein the breaking webs having a smaller cross-sectional area in comparison to the trusses.
US12/108,571 2007-04-26 2008-04-24 Stent Expired - Fee Related US8876885B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007019703 2007-04-26
DE102007019703.0 2007-04-26
DE102007019703A DE102007019703A1 (en) 2007-04-26 2007-04-26 stent

Publications (2)

Publication Number Publication Date
US20080269872A1 true US20080269872A1 (en) 2008-10-30
US8876885B2 US8876885B2 (en) 2014-11-04

Family

ID=39627404

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/108,571 Expired - Fee Related US8876885B2 (en) 2007-04-26 2008-04-24 Stent

Country Status (3)

Country Link
US (1) US8876885B2 (en)
EP (1) EP1985262B1 (en)
DE (1) DE102007019703A1 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8002821B2 (en) 2006-09-18 2011-08-23 Boston Scientific Scimed, Inc. Bioerodible metallic ENDOPROSTHESES
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
US8052744B2 (en) 2006-09-15 2011-11-08 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US8057534B2 (en) 2006-09-15 2011-11-15 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8080055B2 (en) 2006-12-28 2011-12-20 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8128689B2 (en) 2006-09-15 2012-03-06 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8303643B2 (en) 2001-06-27 2012-11-06 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
US20120280535A1 (en) * 2011-05-04 2012-11-08 GM Global Technology Operations LLC System and method for manufacturing magnesium body panels with improved corrosion resistance
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8435281B2 (en) 2009-04-10 2013-05-07 Boston Scientific Scimed, Inc. Bioerodible, implantable medical devices incorporating supersaturated magnesium alloys
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8888841B2 (en) 2010-06-21 2014-11-18 Zorion Medical, Inc. Bioabsorbable implants
JP2015508013A (en) * 2012-02-23 2015-03-16 セロノヴァ・ステント・インコーポレーテッド Stent having at least one connecting member configured to controllably divide INVIVO (in the body)
US8986369B2 (en) 2010-12-01 2015-03-24 Zorion Medical, Inc. Magnesium-based absorbable implants
CN107872968A (en) * 2015-06-03 2018-04-03 安德拉泰克股份有限公司 Support
US20180116835A1 (en) * 2016-10-27 2018-05-03 Cook Medical Technologies Llc Stent with segments capable of uncoupling during expansion
CN113456290A (en) * 2021-06-24 2021-10-01 北京科技大学 Degradable metal skull repairing mesh implant

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197047B1 (en) * 1997-05-23 2001-03-06 BIOTRONIK MESS- UND THERAPIEGERäTE GMBH & CO. INGENIEURBURO BERLIN Stent
US20020111671A1 (en) * 2001-02-15 2002-08-15 Stenzel Eric B. Locking stent
US20030199969A1 (en) * 1998-02-17 2003-10-23 Steinke Thomas A. Expandable stent with sliding and locking radial elements
US20040149294A1 (en) * 2002-12-16 2004-08-05 Gianchandani Yogesh B. Assembly and planar structure for use therein which is expandable into a 3-D structure such as a stent and device for making the planar structure
US20060111772A1 (en) * 2002-08-06 2006-05-25 Icon Medical Corp. Stent with micro-latching hinge joints
US20060122694A1 (en) * 2004-12-03 2006-06-08 Stinson Jonathan S Medical devices and methods of making the same
US20060195175A1 (en) * 2005-02-25 2006-08-31 Abbott Laboratories Vascular Enterprises Limited Modular vascular prosthesis having axially variable properties and improved flexibility and methods of use
US20070005127A1 (en) * 2005-06-17 2007-01-04 Peter Boekstegers Hinged tissue implant and related methods and devices for delivering such an implant
US20070073383A1 (en) * 2002-12-30 2007-03-29 Yip Philip S Drug-eluting stent cover and method of use
US20080195190A1 (en) * 2004-07-30 2008-08-14 Angiomed Gmbh & Co. Medizintechnik Kg Flexible Intravascular Implant
US20080215135A1 (en) * 2005-02-17 2008-09-04 Jacques Seguin Device Allowing the Treatment of Bodily Conduits at an Area of a Bifurcation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6144599A (en) * 1998-09-16 2000-04-03 Isostent, Inc. Linkage stent
US7029492B1 (en) * 1999-03-05 2006-04-18 Terumo Kabushiki Kaisha Implanting stent and dilating device
DE10261822A1 (en) 2002-12-20 2004-07-01 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Helix bridge connection
DE10325128A1 (en) * 2003-06-04 2005-01-05 Qualimed Innovative Medizin-Produkte Gmbh stent
US7323008B2 (en) * 2004-08-09 2008-01-29 Medtronic Vascular, Inc. Flexible stent
EP2614796B1 (en) * 2005-04-25 2020-04-08 Covidien LP Controlled fracture connections for stents

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197047B1 (en) * 1997-05-23 2001-03-06 BIOTRONIK MESS- UND THERAPIEGERäTE GMBH & CO. INGENIEURBURO BERLIN Stent
US20030199969A1 (en) * 1998-02-17 2003-10-23 Steinke Thomas A. Expandable stent with sliding and locking radial elements
US20020111671A1 (en) * 2001-02-15 2002-08-15 Stenzel Eric B. Locking stent
US20060111772A1 (en) * 2002-08-06 2006-05-25 Icon Medical Corp. Stent with micro-latching hinge joints
US20040149294A1 (en) * 2002-12-16 2004-08-05 Gianchandani Yogesh B. Assembly and planar structure for use therein which is expandable into a 3-D structure such as a stent and device for making the planar structure
US20070073383A1 (en) * 2002-12-30 2007-03-29 Yip Philip S Drug-eluting stent cover and method of use
US20080195190A1 (en) * 2004-07-30 2008-08-14 Angiomed Gmbh & Co. Medizintechnik Kg Flexible Intravascular Implant
US20060122694A1 (en) * 2004-12-03 2006-06-08 Stinson Jonathan S Medical devices and methods of making the same
US20080215135A1 (en) * 2005-02-17 2008-09-04 Jacques Seguin Device Allowing the Treatment of Bodily Conduits at an Area of a Bifurcation
US20060195175A1 (en) * 2005-02-25 2006-08-31 Abbott Laboratories Vascular Enterprises Limited Modular vascular prosthesis having axially variable properties and improved flexibility and methods of use
US20070005127A1 (en) * 2005-06-17 2007-01-04 Peter Boekstegers Hinged tissue implant and related methods and devices for delivering such an implant

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303643B2 (en) 2001-06-27 2012-11-06 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
US8128689B2 (en) 2006-09-15 2012-03-06 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
US8052744B2 (en) 2006-09-15 2011-11-08 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US8057534B2 (en) 2006-09-15 2011-11-15 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8002821B2 (en) 2006-09-18 2011-08-23 Boston Scientific Scimed, Inc. Bioerodible metallic ENDOPROSTHESES
US8080055B2 (en) 2006-12-28 2011-12-20 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8715339B2 (en) 2006-12-28 2014-05-06 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8435281B2 (en) 2009-04-10 2013-05-07 Boston Scientific Scimed, Inc. Bioerodible, implantable medical devices incorporating supersaturated magnesium alloys
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US9849008B2 (en) 2010-06-21 2017-12-26 Zorion Medical, Inc. Bioabsorbable implants
US8888841B2 (en) 2010-06-21 2014-11-18 Zorion Medical, Inc. Bioabsorbable implants
US8986369B2 (en) 2010-12-01 2015-03-24 Zorion Medical, Inc. Magnesium-based absorbable implants
US10463511B2 (en) 2011-02-23 2019-11-05 Celonova Stent, Inc. Stent having at least one connecting member configured to controllably sever in vivo
US20120280535A1 (en) * 2011-05-04 2012-11-08 GM Global Technology Operations LLC System and method for manufacturing magnesium body panels with improved corrosion resistance
US8866044B2 (en) * 2011-05-04 2014-10-21 GM Global Technology Operations LLC System and method for manufacturing magnesium body panels with improved corrosion resistance
JP2015508013A (en) * 2012-02-23 2015-03-16 セロノヴァ・ステント・インコーポレーテッド Stent having at least one connecting member configured to controllably divide INVIVO (in the body)
CN107872968A (en) * 2015-06-03 2018-04-03 安德拉泰克股份有限公司 Support
US20180140444A1 (en) * 2015-06-03 2018-05-24 Andratec Gmbh Stent
US10905573B2 (en) * 2015-06-03 2021-02-02 Andratech Gmbh Stent
JP7075660B2 (en) 2015-06-03 2022-05-26 アンドラテック ゲーエムベーハー Stent
US20180116835A1 (en) * 2016-10-27 2018-05-03 Cook Medical Technologies Llc Stent with segments capable of uncoupling during expansion
US10231856B2 (en) * 2016-10-27 2019-03-19 Cook Medical Technologies Llc Stent with segments capable of uncoupling during expansion
CN113456290A (en) * 2021-06-24 2021-10-01 北京科技大学 Degradable metal skull repairing mesh implant

Also Published As

Publication number Publication date
EP1985262A3 (en) 2009-09-30
US8876885B2 (en) 2014-11-04
EP1985262B1 (en) 2013-04-24
DE102007019703A1 (en) 2008-10-30
EP1985262A2 (en) 2008-10-29

Similar Documents

Publication Publication Date Title
US8876885B2 (en) Stent
EP1753368B1 (en) Stent having struts with reverse direction curvature
US6736844B1 (en) Helical stent and method for making same
US9668895B2 (en) Bendable stent
US6607554B2 (en) Universal stent link design
EP1624827B1 (en) Stents made of a material having a low elongation at fracture
US6723118B1 (en) Flexible metal wire stent
US6471720B1 (en) Stent configurations
US8052734B2 (en) Expandable medical device with beneficial agent delivery mechanism
US7951187B2 (en) Stent configurations
US6423090B1 (en) Stent pattern with staged expansion
EP2614796B1 (en) Controlled fracture connections for stents
US9345599B2 (en) Low profile stent with flexible link
EP1563806A1 (en) Connector members for stents
US20070185560A1 (en) Expandable stent
JP2000024116A (en) Supporting structure diametrally expandable in radial direction
US20130226283A1 (en) Offset peak-to-peak stent pattern
JP2009050716A (en) Cannula stent
JP4410468B2 (en) Crimpable lumen endoprosthesis with helical elements
US9925076B2 (en) Stent
WO2018157328A1 (en) Spiral open self-expandable stent

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOTRONIK VI PATENT AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOOTZ, DANIEL;SURBER, BETTINA;HAUSSMANN, MATHIAS;REEL/FRAME:020853/0944;SIGNING DATES FROM 20080404 TO 20080415

Owner name: BIOTRONIK VI PATENT AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOOTZ, DANIEL;SURBER, BETTINA;HAUSSMANN, MATHIAS;SIGNING DATES FROM 20080404 TO 20080415;REEL/FRAME:020853/0944

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551)

Year of fee payment: 4

AS Assignment

Owner name: BIOTRONIK AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOTRONIK VI PATENT AG;REEL/FRAME:047166/0462

Effective date: 20170926

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20221104